FNY Investment Advisers LLC Invests $646,000 in Genmab A/S Sponsored ADR $GMAB

FNY Investment Advisers LLC purchased a new position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 21,000 shares of the company’s stock, valued at approximately $646,000.

A number of other institutional investors and hedge funds have also bought and sold shares of GMAB. Paradigm Biocapital Advisors LP bought a new position in shares of Genmab A/S in the third quarter worth approximately $117,063,000. Orbis Allan Gray Ltd increased its position in shares of Genmab A/S by 38.7% during the second quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock valued at $163,635,000 after acquiring an additional 2,209,659 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Genmab A/S by 152.3% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock worth $71,367,000 after acquiring an additional 2,084,966 shares during the last quarter. Deep Track Capital LP purchased a new position in Genmab A/S in the 3rd quarter worth approximately $14,760,000. Finally, Federated Hermes Inc. bought a new position in Genmab A/S in the 3rd quarter valued at approximately $12,972,000. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Stock Performance

GMAB stock opened at $27.50 on Friday. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01. Genmab A/S Sponsored ADR has a 1 year low of $17.24 and a 1 year high of $35.43. The company has a market cap of $17.67 billion, a P/E ratio of 17.74, a price-to-earnings-growth ratio of 1.23 and a beta of 0.97. The stock’s fifty day moving average price is $28.95 and its 200-day moving average price is $30.42.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Tuesday, February 17th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). The firm had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. On average, equities analysts forecast that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on GMAB. Truist Financial raised Genmab A/S to a “strong-buy” rating in a report on Wednesday, March 25th. HC Wainwright increased their price objective on Genmab A/S from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Guggenheim reduced their price objective on Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a report on Monday, February 23rd. Wall Street Zen downgraded shares of Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Finally, Wolfe Research began coverage on shares of Genmab A/S in a report on Friday, March 27th. They set an “outperform” rating and a $32.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $39.36.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.